Catalent Names Alessandro Maselli President and Chief Operating Officer

SOMERSET, N.J.–(BUSINESS WIRE)–Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced
delivery technologies and development solutions for drugs, biologics and
consumer health products, today announced that Senior Vice President,
Global Operations Alessandro Maselli has been appointed President and
Chief Operating Officer, a new position within Catalent. Maselli will
continue to report to John Chiminski, Chair and CEO of Catalent.

“Catalent has enjoyed strong organic growth and integrated several
strategic acquisitions since becoming a publicly traded company. We have
now reached a stage where we can benefit from more executive team
bandwidth to permit the necessary focus on both external opportunities
and on operational excellence across our broad scope of businesses,”
said Chiminski. “Alessandro will focus on the growth of our existing
businesses, drive integration across our offerings, and meet customers’
ever-expanding needs for improved drug development and supply, while I
will focus on long-term strategic growth, exploring future
transformational opportunities as well as building deeper partnerships
with investors, customers, suppliers, and other external constituencies.”

Effective immediately, Catalent’s four Business Unit Presidents will
report to Maselli, who will also oversee the functional leaders of
global sales and marketing and global quality and regulatory affairs.
Management of the daily operations at Catalent’s network of facilities
around the world will be fully integrated into the business units. The
administrative functions, including Finance, Human Resources and Legal,
will continue to report to Chiminski.

“I am honored to be given this opportunity,” said Maselli. “I am
confident that we have everything we need to continue to win as we
embark on this new chapter. We are expanding our global network,
investing in growth-driving capabilities, and elevating our performance
to help customers and patients around the world.”

Prior to this appointment, Alessandro Maselli was Senior Vice President
of Catalent’s Global Operations. He joined Catalent in 2010 as Director
of Operations at Catalent’s pharmaceutical, nutritional, and cosmetics
plant in Aprilia, Italy. In 2013, Maselli was appointed General Manager
of Zydis® operations at Catalent’s facility in Swindon, U.K,
and in 2015 he became Vice President of Operations, Europe, for
Catalent’s Drug Delivery Solutions business unit.

Prior to Catalent, Maselli held operational and business leadership
roles at Alstom, SGS, and ABB, in roles spanning the automotive and
transportation industries as well as consultancy services. Maselli began
his career as an automation systems engineer in the food industry. A
native of Italy, Maselli earned a master’s degree in engineering from
the University of Rome.

About Catalent, Inc.

Catalent, Inc. (NYSE: CTLT) is the leading global provider of advanced
delivery technologies and development solutions for drugs, biologics and
consumer health products. With over 85 years serving the industry,
Catalent has proven expertise in bringing more customer products to
market faster, enhancing product performance and ensuring reliable
clinical and commercial product supply. Catalent employs over 11,000
people, including over 1,800 scientists, at more than 30 facilities
across five continents, and in fiscal 2018 generated approximately $2.5
billion in annual revenue. Catalent is headquartered in Somerset, New
Jersey. For more information, visit

More products. Better treatments. Reliably supplied.™


Chris Halling
+44 (0)7580 041073

Richard Kerns
+44 (0) 161 728 5880

Investor Relations:
Thomas Castellano
+1 (732) 537-6175

error: Content is protected !!